Antiparasitics in Cancer Treatment Study

In fact, it's the largest human cancer

study with these antiparasitics.

So what we had, we had about two hundred cancer patients

prescribed

ivermectin and mebendazole. About half reported

either cancer disappearance or tumor regression, tumor

shrinkage, and about thirty-six percent reported to

have their cancers stabilized. So that is a eighty-four point

four percent clinical benefit ratio, uh, absolutely huge.

There's over a hundred preclinical studies, so

laboratory and in the animals, of ivermectin, mebendazole,

fenbendazole, and cancer. And there are over twelve distinct

anticancer mechanisms across more than twelve cancer

types with these antiparasitic compounds, and there's three

key ones. One is ivermectin targets cancer stem

cells.

Chemo does not get rid of those. Those are the source of some of these

cancers that keep them... They, they, they basically cause

reoccurrence of cancers even if you appear to eliminate them.

So you wanna get rid of those. Ivermectin appears to in the laboratory

studies. It also, mebendazole disrupts what's called

microtubules. This is critical for cell division in

cancer cells. So you cut that off, uh, these cancer cells will have a

hard time to divide. And mebendazole also

inhibits glucose metabolism in cancer cells,

which, um, cancers love to feed on glucose.

They love sugar.

You cut off the, their ability to uptake the sugar,

they're going to have a

hard time to propagate in the body.

So we have very promising preclinical mechanisms

explaining why we saw such a positive clinical benefit

ratio in the human data